Ergoteles LLC Mannkind Corp Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$3.95 - $5.63 $162,368 - $231,426	41,106 Added 128.69%	73,049 $299,000
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $96,467 - $171,533	31,943 New	31,943 $168,000
Q2 2022 Aug 12, 2022	BUY	$2.67 - $4.77 $468,272 - $836,576	175,383 Added 127.01%	313,465 $1.19 Million
Q1 2022 May 13, 2022	BUY	$2.62 - $4.45 $177,470 - $301,429	67,737 Added 96.29%	138,082 $508,000
Q4 2021 Feb 14, 2022	SELL	$4.05 - $5.37 $717,388 - $951,204	-177,133 Reduced 71.58%	70,345 $307,000
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $962,689 - $1.36 Million	247,478 New	247,478 $1.08 Million

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.75B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.